Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis

BackgroundPatients with systemic lupus erythematosus (SLE) are particularly vulnerable to infections, with herpes zoster (HZ) being the most common opportunistic infection. This meta-analysis aimed to systematically review the available literature on the prevalence, incidence, and risk factors of HZ...

Full description

Saved in:
Bibliographic Details
Main Authors: Hong-Fei Wang, Yan Gao, Zheng Lin, Shan Liu, Yi Cao, Qiu-Shuang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544218/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849412876877430784
author Hong-Fei Wang
Hong-Fei Wang
Yan Gao
Zheng Lin
Shan Liu
Yi Cao
Qiu-Shuang Li
author_facet Hong-Fei Wang
Hong-Fei Wang
Yan Gao
Zheng Lin
Shan Liu
Yi Cao
Qiu-Shuang Li
author_sort Hong-Fei Wang
collection DOAJ
description BackgroundPatients with systemic lupus erythematosus (SLE) are particularly vulnerable to infections, with herpes zoster (HZ) being the most common opportunistic infection. This meta-analysis aimed to systematically review the available literature on the prevalence, incidence, and risk factors of HZ in SLE patients.MethodsA comprehensive search through Embase, PubMed, Web of Science, and Cochrane Library was conducted for studies published up to November 1, 2024. Both observational studies (including cohort, case-control, and cross-sectional) and randomized controlled trials (RCTs) were included, with study types selected according to the specific objectives. Funnel plots and Egger’s test were employed to assess publication bias. Hazard ratios (HRs) and odds ratios (ORs) were converted to relative risks (RRs), and pooled estimates were calculated using a fixed-effect or random-effects model.ResultsA total of 51 studies with 246, 822 SLE patients were included in this meta-analysis. The pooled prevalence and incidence of SLE-HZ were 12.3% (95%CI 10.5-14.1) and 22.0 cases per 1000 person-years (95%CI 17.4-27.9). Glucocorticoids use (RRs=2.83, 95%CI 2.10-3.81), cyclophosphamide use (RRs=2.52, 95%CI 1.60-3.98), mycophenolate mofetil use (RRs=3.00, 95%CI 1.07-8.40), azathioprine use (RRs=1.40, 95%CI 1.18-1.67), anifrolumab use (RRs=2.59, 95%CI 1.52-4.41), having lymphopenia (RRs=2.31, 95%CI 1.54-3.46), and the presence of comorbid conditions such as renal involvement (RRs= 1.80, 95%CI 1.34-2.42) were identified to increase the risk of HZ in SLE patients.ConclusionThe existing evidence highlights the both high prevalence and incidence of HZ in SLE patients. By identifying risk factors associated with the development of HZ in SLE patients, optimization of management strategies and treatment choices can be achieved. Concurrently, physicians could be better equipped to choose patients who would most likely gain from the HZ vaccine.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024331310, identifier CRD42024331310.
format Article
id doaj-art-2f4ae32d4e5c48f5be4d366fe74bfa35
institution Kabale University
issn 1664-3224
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-2f4ae32d4e5c48f5be4d366fe74bfa352025-08-20T03:34:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.15442181544218Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysisHong-Fei Wang0Hong-Fei Wang1Yan Gao2Zheng Lin3Shan Liu4Yi Cao5Qiu-Shuang Li6The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaFirst School of Clinical Medicine, Zhejiang Chinese Medicine University, Hangzhou, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaFirst School of Clinical Medicine, Zhejiang Chinese Medicine University, Hangzhou, ChinaResearch and Development Department, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaResearch and Development Department, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaBackgroundPatients with systemic lupus erythematosus (SLE) are particularly vulnerable to infections, with herpes zoster (HZ) being the most common opportunistic infection. This meta-analysis aimed to systematically review the available literature on the prevalence, incidence, and risk factors of HZ in SLE patients.MethodsA comprehensive search through Embase, PubMed, Web of Science, and Cochrane Library was conducted for studies published up to November 1, 2024. Both observational studies (including cohort, case-control, and cross-sectional) and randomized controlled trials (RCTs) were included, with study types selected according to the specific objectives. Funnel plots and Egger’s test were employed to assess publication bias. Hazard ratios (HRs) and odds ratios (ORs) were converted to relative risks (RRs), and pooled estimates were calculated using a fixed-effect or random-effects model.ResultsA total of 51 studies with 246, 822 SLE patients were included in this meta-analysis. The pooled prevalence and incidence of SLE-HZ were 12.3% (95%CI 10.5-14.1) and 22.0 cases per 1000 person-years (95%CI 17.4-27.9). Glucocorticoids use (RRs=2.83, 95%CI 2.10-3.81), cyclophosphamide use (RRs=2.52, 95%CI 1.60-3.98), mycophenolate mofetil use (RRs=3.00, 95%CI 1.07-8.40), azathioprine use (RRs=1.40, 95%CI 1.18-1.67), anifrolumab use (RRs=2.59, 95%CI 1.52-4.41), having lymphopenia (RRs=2.31, 95%CI 1.54-3.46), and the presence of comorbid conditions such as renal involvement (RRs= 1.80, 95%CI 1.34-2.42) were identified to increase the risk of HZ in SLE patients.ConclusionThe existing evidence highlights the both high prevalence and incidence of HZ in SLE patients. By identifying risk factors associated with the development of HZ in SLE patients, optimization of management strategies and treatment choices can be achieved. Concurrently, physicians could be better equipped to choose patients who would most likely gain from the HZ vaccine.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024331310, identifier CRD42024331310. https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544218/fullsystemic lupus erythematosusherpes zosterincidenceprevalencerisk factor
spellingShingle Hong-Fei Wang
Hong-Fei Wang
Yan Gao
Zheng Lin
Shan Liu
Yi Cao
Qiu-Shuang Li
Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
Frontiers in Immunology
systemic lupus erythematosus
herpes zoster
incidence
prevalence
risk factor
title Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
title_full Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
title_fullStr Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
title_full_unstemmed Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
title_short Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
title_sort prevalence incidence and risk factors for herpes zoster in systemic lupus erythematosus a systematic review and meta analysis
topic systemic lupus erythematosus
herpes zoster
incidence
prevalence
risk factor
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544218/full
work_keys_str_mv AT hongfeiwang prevalenceincidenceandriskfactorsforherpeszosterinsystemiclupuserythematosusasystematicreviewandmetaanalysis
AT hongfeiwang prevalenceincidenceandriskfactorsforherpeszosterinsystemiclupuserythematosusasystematicreviewandmetaanalysis
AT yangao prevalenceincidenceandriskfactorsforherpeszosterinsystemiclupuserythematosusasystematicreviewandmetaanalysis
AT zhenglin prevalenceincidenceandriskfactorsforherpeszosterinsystemiclupuserythematosusasystematicreviewandmetaanalysis
AT shanliu prevalenceincidenceandriskfactorsforherpeszosterinsystemiclupuserythematosusasystematicreviewandmetaanalysis
AT yicao prevalenceincidenceandriskfactorsforherpeszosterinsystemiclupuserythematosusasystematicreviewandmetaanalysis
AT qiushuangli prevalenceincidenceandriskfactorsforherpeszosterinsystemiclupuserythematosusasystematicreviewandmetaanalysis